Blonanserin is an atypical
antipsychotic drug (APD) which, compared to other atypical APDs, is a relatively selective
serotonin (5-HT)2A and
dopamine D2 antagonist. Comparing
blonanserin with more broadly acting atypical APDs could be useful to test the contributions of actions at other monoamine receptors, e.g. 5-HT1A receptors, to the reversal of PCP-induced novel object recognition (NOR) deficit. In this study, we tested the effect of
blonanserin alone, and in combination with 5-HT1A agents, on NOR deficit induced by subchronic treatment with the
N-methyl-D-aspartate (
NMDA) receptor antagonist,
phencyclidine (PCP; 2 mg/kg), b.i.d., for 7 days.
Blonanserin, 1mg/kg, but not 0.3mg/kg, improved the PCP-induced NOR deficit. However, at 1mg/kg, object exploration was diminished. Co-administration of sub-effective doses of
blonanserin (0.3 mg/kg) and the 5-HT1A partial agonist,
tandospirone (0.2 mg/kg), significantly reversed the NOR deficit without diminishing activity during the acquisition or retention periods. The combination of WAY100635 (0.6 mg/kg), a
5-HT1A antagonist, and
blonanserin (1 mg/kg), also diminished object exploration which prevented assessment of the effect of this combination on NOR. WAY100635 (0.6 mg/kg) blocked the ameliorating effect of
risperidone (0.1 mg/kg), another atypical APD with low affinity for 5-HT1A receptors, but did not impair exploration. These results suggest that blonansein and
risperidone, atypical APDs which lack a direct action on 5-HT1A receptors require
5-HT1A receptor stimulation to reverse the subchronic PCP-induced NOR deficit and provide a support for clinical trial of
blonanserin in combination with
tandospirone to ameliorate
cognitive impairment in
schizophrenia and to have fewer side effects.